Omnicell的Q2 EPS超过估计,得到混合分析师的评分和价格目标的提高。 Omnicell's Q2 EPS exceeded estimates, receiving mixed analyst ratings and price target increases.

美国医疗保健公司Omnicell的评价不一,包括美国银行从34美元提高到44美元的目标价格,并提高"买入"评级,巴克莱从低权重升级到同权重,目标价格为39美元. Omnicell, a US-based healthcare firm, has received mixed ratings from analysts, including Bank of America's price target increase from $34.00 to $44.00 and a "buy" rating, and Barclays' upgrade from underweight to equal weight with a $39.00 price target. Omnicell的Q2 EPS 0.51美元超过了协商一致的估计数0.14美元,该公司为保健系统和药房提供药品管理解决方案和坚持使用工具。 Omnicell's Q2 EPS of $0.51 surpassed the consensus estimate of $0.14, and the company offers medication management solutions and adherence tools for healthcare systems and pharmacies.